Niagen Bioscience (NAGE) announced a new partnership with Olympia Pharmaceuticals to compound and distribute pharmaceutical-grade Niagen for the Company’s Niagen Plus intravenous and injectable products. Olympia Pharmaceuticals joins Wells Pharma of Houston, diversifying the Company’s 503B network and supply chain capabilities to support continued growth across its clinic footprint and expand access to the Company’s innovative Niagen Plus product pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience collaborates with USP to establish USP monograph
- Niagen announces first cruise ship clinic partnership with OneSpaWorld
- Niagen Bioscience Doubles Share Repurchase Authorization to $20M
- Niagen Bioscience increases share repurchase program to $20M
- VGT vs. VOO vs. VDC: Which Vanguard ETF Has More Upside in 2026?